Literature DB >> 24478195

Two mutations in IFITM5 causing distinct forms of osteogenesis imperfecta.

Encarna Guillén-Navarro1, María Juliana Ballesta-Martínez, María Valencia, Ana María Bueno, Victor Martinez-Glez, Vanesa López-González, Birute Burnyte, Algirdas Utkus, Pablo Lapunzina, Victor L Ruiz-Perez.   

Abstract

The IFITM5 gene has recently been found to be mutated in patients with autosomal dominant osteogenesis imperfecta (OI) type V. This form of OI is characterized by distinctive clinical manifestations, including hyperplastic callus formation at the site of fractures, calcification of the interosseous membrane of the forearm, and dislocation of the head of the radius. Notably, in spite of the fact that a considerable number of patients with IFITM5 mutations have been identified, to date all of them have been shown to have the same heterozygous mutation (c.-14C>T). Herein, we describe one patient with a de novo c.119C>T heterozygous mutation in IFITM5, which predicts p.Ser40Leu, and another with the recurrent c.-14C>T transition that was also apparently de novo. While the patient with the p.Ser40Leu mutation had none of the typical signs of OI type V and was diagnosed with limb shortening at prenatal stages, the patient with the c.-14C>T mutation developed hyperplastic calluses and had calcification of the forearm interosseous membrane. This study challenges the lack of allelic and clinical heterogeneity in IFITM5 mutations.
© 2014 Wiley Periodicals, Inc.

Entities:  

Keywords:  BRIL; IFITM5; OI type V; bone development; osteogenesis imperfecta

Mesh:

Substances:

Year:  2014        PMID: 24478195     DOI: 10.1002/ajmg.a.36409

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  15 in total

Review 1.  IFITM5 mutations and osteogenesis imperfecta.

Authors:  Nobutaka Hanagata
Journal:  J Bone Miner Metab       Date:  2015-06-02       Impact factor: 2.626

Review 2.  Osteogenesis imperfecta due to mutations in non-collagenous genes: lessons in the biology of bone formation.

Authors:  Joan C Marini; Adi Reich; Simone M Smith
Journal:  Curr Opin Pediatr       Date:  2014-08       Impact factor: 2.856

3.  Type V OI primary osteoblasts display increased mineralization despite decreased COL1A1 expression.

Authors:  Adi Reich; Alison S Bae; Aileen M Barnes; Wayne A Cabral; Aleksander Hinek; Jennifer Stimec; Suvimol C Hill; David Chitayat; Joan C Marini
Journal:  J Clin Endocrinol Metab       Date:  2014-11-11       Impact factor: 5.958

4.  Hypermineralization and High Osteocyte Lacunar Density in Osteogenesis Imperfecta Type V Bone Indicate Exuberant Primary Bone Formation.

Authors:  Stéphane Blouin; Nadja Fratzl-Zelman; Francis H Glorieux; Paul Roschger; Klaus Klaushofer; Joan C Marini; Frank Rauch
Journal:  J Bone Miner Res       Date:  2017-06-26       Impact factor: 6.741

Review 5.  Genetic causes and mechanisms of Osteogenesis Imperfecta.

Authors:  Joohyun Lim; Ingo Grafe; Stefanie Alexander; Brendan Lee
Journal:  Bone       Date:  2017-02-15       Impact factor: 4.398

6.  Clinical and Molecular Characterization of Osteogenesis Imperfecta Type V.

Authors:  Evelise Brizola; Eduardo P Mattos; Jessica Ferrari; Patricia O A Freire; Raquel Germer; Juan C Llerena; Têmis M Félix
Journal:  Mol Syndromol       Date:  2015-09-03

Review 7.  Osteogenesis Imperfecta: Mechanisms and Signaling Pathways Connecting Classical and Rare OI Types.

Authors:  Milena Jovanovic; Gali Guterman-Ram; Joan C Marini
Journal:  Endocr Rev       Date:  2022-01-12       Impact factor: 19.871

Review 8.  Recent developments in osteogenesis imperfecta.

Authors:  Joseph L Shaker; Carolyne Albert; Jessica Fritz; Gerald Harris
Journal:  F1000Res       Date:  2015-09-07

9.  Monoallelic and biallelic CREB3L1 variant causes mild and severe osteogenesis imperfecta, respectively.

Authors:  Rachel B Keller; Thao T Tran; Shawna M Pyott; Melanie G Pepin; Ravi Savarirayan; George McGillivray; Deborah A Nickerson; Michael J Bamshad; Peter H Byers
Journal:  Genet Med       Date:  2017-08-17       Impact factor: 8.822

Review 10.  Membrane Interference Against HIV-1 by Intrinsic Antiviral Factors: The Case of IFITMs.

Authors:  Federico Marziali; Andrea Cimarelli
Journal:  Cells       Date:  2021-05-11       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.